Clinical Features of Systemic Sclerosis–Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes

Objective To describe the clinical characteristics and outcomes of systemic sclerosis–mixed connective tissue disease (SSc–MCTD) SSc overlap syndrome. Methods We included patients from Australian Scleroderma Cohort Study who met American College Rheumatology/European Alliance Associations for Rheumatology criteria SSc. Three mutually exclusive groups were created: SSc–MCTD, overlap, only. Univariate comparison features was performed by analysis variance or chi-square test. Survival using Kaplan-Meier (KM) curves Cox proportional hazards regression models. Results Of 1,728 patients, 97 (5.6%) had 126 (7.3%) overlap. Those with MCTD–SSc more commonly Asian (18.3% versus 10.1% in 3.6% only; P < 0.0001) younger at onset (38.4 years 46.5 46.8 years, 0.0001). SSc–MCTD likely to have limited cutaneous All 3 similar frequency interstitial lung (ILD), although pulmonary arterial hypertension (PAH) less common Synovitis myositis than KM showed better survival only (P = 0.011), but this not significant after adjustment sex age onset. SSc-specific antibodies prognostic markers, antinuclear antibody centromere anti-RNP conferring anti–Scl-70 anti–RNA polymerase III 0.005). Patients lower mortality following diagnosis ILD PAH Conclusion This study provides insights into shows that are associated anti-RNA antibodies.